ConductScience.org, home

Paper33765296

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.

Lamb YN. Drugs, 2021. Cited by 124 papers, by iCite.

Cite this record

ConductScience Library. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. Papers, record 33765296. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33765296

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
PubMed
Journal
Drugs
PubMed
Year
2021
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
124
iCite
Relative citation ratio, by iCite
8.69
iCite
Revised in PubMed
2024-09-26
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lamb YNYvette N

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Idiopathic Pulmonary FibrosisMajor topic
IndolesMajor topic
Lung Diseases, InterstitialMajor topic
Protein Kinase InhibitorsMajor topic
Protein-Tyrosine KinasesMajor topic
Humans

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Erratum in33847978Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.https://conductscience.org/library/papers/33847978PubMed
Erratum in34050918Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.https://conductscience.org/library/papers/34050918PubMed

Download CSV of comments and corrections

References63

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126400368Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.Respir Res2015https://conductscience.org/library/papers/26400368PubMed
226063212Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.Drugs2015https://conductscience.org/library/papers/26063212PubMed
331914963Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.BMC Pulm Med2020https://conductscience.org/library/papers/31914963PubMed
428861727Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?Drugs Aging2017https://conductscience.org/library/papers/28861727PubMed
532010718Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study.ERJ Open Res2020https://conductscience.org/library/papers/32010718PubMed
631566307Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.N Engl J Med2019https://conductscience.org/library/papers/31566307PubMed
729490307Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.Respiration2018https://conductscience.org/library/papers/29490307PubMed
820813056Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.Arthritis Res Ther2010https://conductscience.org/library/papers/20813056PubMed
931016670Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.Clin Pharmacokinet2019https://conductscience.org/library/papers/31016670PubMed
1026843176Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.BMC Med2016https://conductscience.org/library/papers/26843176PubMed
1130971229Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials.Respir Res2019https://conductscience.org/library/papers/30971229PubMed
1230814139Fibrosing interstitial lung diseases: knowns and unknowns.Eur Respir Rev2019https://conductscience.org/library/papers/30814139PubMed
1331179001Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.BMJ Open Respir Res2019https://conductscience.org/library/papers/31179001PubMed
1430224318Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.Lancet Respir Med2019https://conductscience.org/library/papers/30224318PubMed
1527672117Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.Thorax2017https://conductscience.org/library/papers/27672117PubMed
1633412120Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.Lancet Respir Med2021https://conductscience.org/library/papers/33412120PubMed
1729946005Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.Eur Respir J2018https://conductscience.org/library/papers/29946005PubMed
1832767182Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data.Adv Ther2020https://conductscience.org/library/papers/32767182PubMed
1930665517Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.Respir Med2019https://conductscience.org/library/papers/30665517PubMed
2029106740Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment.J Clin Pharmacol2018https://conductscience.org/library/papers/29106740PubMed

See all 63 referencesDownload CSV of references

Cited by96

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 124 citations.

PMIDTitleJournalYearIn PapersSource
42907787Nintedanib alleviates pulmonary inflammation and fibrosis in mice with silicosis.BMC Pulm Med2026https://conductscience.org/library/papers/42907787PubMed
42877793The unequal burden of interstitial lung disease mortality in older US adults: a 22-year analysis and projections to 2030.Arch Med Sci2026https://conductscience.org/library/papers/42877793PubMed
42820177Nintedanib-Associated Generalized Body Swelling in a Patient With Idiopathic Pulmonary Fibrosis: A Case Report.Cureus2026https://conductscience.org/library/papers/42820177PubMed
42786726Harmine Derivative H-2-104 Alleviates Echinococcus granulosus-Induced Pulmonary Fibrosis in Mice by Inhibiting Fibroblast Activation and Inducing DNA Damage.J Immunol Res2026https://conductscience.org/library/papers/42786726PubMed
42737450Association of PDGFRB, VEGFR2, and TGFB1 Gene Polymorphisms with Nintedanib Efficacy and Adverse Effects in Patients with Progressive Pulmonary Fibrosis.Int J Mol Sci2026https://conductscience.org/library/papers/42737450PubMed
42696184Combined Anti-PD-1/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment.Curr Treat Options Oncol2026https://conductscience.org/library/papers/42696184PubMed
42663780β-carboline derivative Z86 alleviates pulmonary fibrosis via suppressing TGF-β/Smad signaling.Nat Prod Bioprospect2026https://conductscience.org/library/papers/42663780PubMed
42656641Cryobiopsy at the dawn of fibrosis: unlocking early diagnosis and therapeutic windows.Front Med (Lausanne)2026https://conductscience.org/library/papers/42656641PubMed
42650804In Vitro Assessment of Nintedanib in Keratoconus Corneal Stromal Microenvironment.Biomolecules2026https://conductscience.org/library/papers/42650804PubMed
42645433A CSF-1R Ig4-5 Domain-Targeting Antibody for the Treatment of Idiopathic Pulmonary Fibrosis.Antibodies (Basel)2026https://conductscience.org/library/papers/42645433PubMed
42644872Interstitial Lung Disease in the United States: CDC Mortality Trends (1999-2024).Adv Respir Med2026https://conductscience.org/library/papers/42644872PubMed
42509443Pirfenidone combined with nintedanib in connective tissue disease - associated interstitial lung disease with radiologic progression during antifibrotic monotherapy: A case series.Clin Rheumatol2026https://conductscience.org/library/papers/42509443PubMed
42334622Salvinorin A Alleviates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting M2 Macrophage Polarization and Macrophage-to-Myofibroblast Transition.Lung2026https://conductscience.org/library/papers/42334622PubMed
42297840Network-informed multi-trait genomic analysis decodes the shared genetic architecture and therapeutic landscape of pelvic floor disorders.NPJ Aging2026https://conductscience.org/library/papers/42297840PubMed
42115887Comparative efficacy and safety of monotherapy and combination pharmacotherapies for idiopathic pulmonary fibrosis: a network meta-analysis of randomized controlled trials.BMC Pulm Med2026https://conductscience.org/library/papers/42115887PubMed
42112343Kangxianhuanji formula and its component rutin ameliorate acute exacerbation of idiopathic pulmonary fibrosis by targeting GLUT1 to suppress HIF-1α-mediated glycolysis.Front Immunol2026https://conductscience.org/library/papers/42112343PubMed
42039347Nintedanib combined with anticoagulant therapy in advanced lung cancer complicated with pulmonary fibrosis and pulmonary embolism: two case reports and clinical decision-making analysis.Front Cardiovasc Med2026https://conductscience.org/library/papers/42039347PubMed
41750384Effects of Nintedanib on Orofacial Fibroblasts and Myoblasts.Biomolecules2026https://conductscience.org/library/papers/41750384PubMed
41731806
Correlation between red cell distribution width to total calcium ratio and in-hospital mortality in patients with non-idiopathic pulmonary fibrosis interstitial lung diseases: A retrospective cohort study from the MIMIC-IV database.
Medicine (Baltimore)2026https://conductscience.org/library/papers/41731806PubMed
41694584Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response.Int J Biol Sci2026https://conductscience.org/library/papers/41694584PubMed

See all 96 cited byDownload CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33765296

GET https://conductscience.org/api/papers/v1/33765296/references?page=2